BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders
On March 20, 2019, Bioanalytical Systems Inc. (the “Company”) held its annual meeting of shareholders at its corporate offices located at 2701 Kent Avenue, West Lafayette, IN 47906. A total of 7,611,085 shares of the Company’s common stock outstanding and entitled to vote were present at the meeting in person or by proxy. The following is a summary of the matters voted on at the meeting.
| a.) |
Two Class I members of the Board of Directors were elected to serve a three-year term ending in 2022 with the following votes cast: |
| Nominee |
For |
Withheld |
Broker Non-Vote |
|
| R. Matthew Neff |
4,280,310 |
458,171 |
2,872,604 |
| Robert W. Leasure, Jr. |
4,526,988 |
211,493 |
2,872,604 |
| b.) |
The appointment of RSM US LLP as our independent registered public accountants for fiscal 2019 was ratified by the following shareholder vote: |
| Vote Type |
Voted |
|
| For |
7,539,872 |
| Against |
54,343 |
| Abstain |
16,870 |
| c.) |
The proposal to approve, on an advisory basis, the compensation of the company’s named executive officers, as disclosed in the proxy statement, passed with the following votes cast: |
| Vote Type |
Voted |
|
| For |
2,952,416 |
| Against |
178,807 |
| Abstain |
1,607,258 |
| Broker Non-votes |
2,872,604 |
| d.) |
The proposal to approve, on an advisory basis, the frequency of future advisory votes on the compensation of the company’s named executive officers, as disclosed in the proxy statement passed as every three years with the following votes cast: |
| Vote Type |
Voted |
|
| 1 Year |
1,175,944 |
| 2 Years |
1,613,481 |
| 3 Years |
1,900,343 |
| Abstain |
48,713 |
| Broker Non-Votes |
2,872,604 |
About BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI)
Bioanalytical Systems, Inc. (BASi) is a contract research organization (CRO) providing drug discovery and development services and analytical instruments. The Company operates through two segments: contract research services and research products. Its contract research services segment provides research and development support on a contract basis directly to pharmaceutical companies. Its research products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. Its Culex family of robotic automated dose delivery, blood and other biofluids sampling and physiological parameters measurement systems enable researchers to determine pharmacokinetic/pharmacodynamic (PK/PD) profiles of drugs in large and small animal models. The Company’s bioanalytical services group supports research, preclinical and clinical programs.
